Search Results - Helene Karcher

  • Showing 1 - 9 results of 9
Refine Results
  1. 1

    Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma. by Witold Wiecek, Helene Karcher

    Published in PLoS ONE (2016-01-01)
    Get full text
    Article


  2. 2

    Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line tr... by Billy Amzal, Shuai Fu, Jie Meng, Johanna Lister, Helene Karcher

    Published in PLoS ONE (2017-01-01)
    Get full text
    Article


  3. 3

    Real-World Persistence and Treatment Interval in Patients with Diabetic Macular Edema Treated with Anti-Vascular Endothelial Growth Factors in the USA by Sophie J. Bakri, Marie-Noelle Delyfer, Jakob Grauslund, Steffen Andersen, Helene Karcher

    Published in Ophthalmology and Therapy (2023-06-01)
    Get full text
    Article


  4. 4

    Real-World Frequency and Management of Ocular Adverse Events in Eyes with Neovascular Age-Related Macular Degeneration Treated with Brolucizumab by Ryan Zubricky, Jasmyne McCoy, Richard Donkor, David G. Miller, Nina Sonbolian, Andrew Heaney, Ver Bilano, Helene Karcher, Joseph M. Coney

    Published in Ophthalmology and Therapy (2023-06-01)
    Get full text
    Article


  5. 5

    Visual Acuity Outcomes and Influencing Factors in a Cohort of UK Real-World Diabetic Macular Oedema Patients During the First Two Years of Anti-VEGF Treatment by Qing Wen, Helene Karcher, David M. Wright, Samriddhi Buxy Sinha, Usha Chakravarthy, Catarina Santos, Franklin Igwe, Recivall Salongcay, Katie Curran, Tunde Peto

    Published in Pharmaceutics (2025-01-01)
    Get full text
    Article


  6. 6

    Real-World Outcomes of Brolucizumab Treatment in Japanese Patients with Neovascular Age-Related Macular Degeneration: A 12-Month, Multicenter Study by Masayuki Ohnaka, Yoichi Sakurada, Atsushi Hayashi, Kazuaki Kadonosono, Hitoshi Ohno, Ryusaburo Mori, Hidetaka Matsumoto, Ippei Nagamori, Yuki Murata, Tina Maio-Twofoot, Helene Karcher, Hidenori Takahashi

    Published in Ophthalmology and Therapy (2025-05-01)
    Get full text
    Article


  7. 7

    Real-World Safety Outcomes with Brolucizumab in Neovascular Age-Related Macular Degeneration: Findings from the IRIS® Registry by Marco A. Zarbin, Mathew W. MacCumber, Helene Karcher, Eser Adiguzel, Andrew Mayhook, Andrew LaPrise, Ver L. Bilano, Franklin Igwe, Michael S. Ip, Charles C. Wykoff

    Published in Ophthalmology and Therapy (2024-03-01)
    Get full text
    Article


  8. 8

    The “RCT augmentation”: a novel simulation method to add patient heterogeneity into phase III trials by Helene Karcher, Shuai Fu, Jie Meng, Mikkel Zöllner Ankarfeldt, Orestis Efthimiou, Mark Belger, Josep Maria Haro, Lucien Abenhaim, Clementine Nordon, on behalf of the GetReal Consortium Work Package 2

    Published in BMC Medical Research Methodology (2018-07-01)
    Get full text
    Article


  9. 9

    Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration by Joseph M. Coney, Ryan Zubricky, Samriddhi Buxy Sinha, Nina Sonbolian, Lujia Zhou, Thomas P. Hull, Shawn A. Lewis, David G. Miller, Michael A. Novak, Scott D. Pendergast, Hang Pham, Sean M. Platt, Llewelyn J. Rao, Jerome P. Schartman, Lawrence J. Singerman, Richard Donkor, Margaret Fink, Jasmyne McCoy, Helene Karcher

    Get full text
    Article


Search Tools: